Abstract: Polycyclic aromatic hydrocarbons (PAHs), prevalent contaminants in our environment, in many occupations, and in first and second-hand smoke, pose significant adverse health effects. Most research focused on the genotoxic high molecular weight PAHs (e.g., benzo[a]pyrene), however, the nongenotoxic low molecular weight (LMW) PAHs are emerging as potential co-carcinogens and tumor promoters known to dysregulate gap junctional intercellular communication (GJIC), activate mitogen activated protein kinase pathways, and induce the release of inflammatory mediators. We hypothesize that inflammatory mediators resulting from LMW PAH exposure in mouse lung epithelial cell lines are involved in the dysregulation of GJIC. We used mouse lung epithelial cell lines and an alveolar macrophage cell line in the presence of a binary PAH mixture (1:1 ratio of fluoranthene and 1-methylanthracene; PAH mixture). Parthenolide, a pan-inflammation inhibitor, reversed the PAH-induced inhibition of GJIC, the decreased CX43 expression, and the induction of KC and TNF. To further determine the direct role of a cytokine in regulating GJIC, recombinant TNF (rTNF) was used to inhibit GJIC and this response was further enhanced in the presence of the PAH mixture. Collectively, these findings support a role for inflammation in regulating GJIC and the potential to target these early stage cancer pathways for therapeutics.
Introduction
Polycyclic aromatic hydrocarbons (PAH) are abundant toxicants in the environment (air, water, soil), occupational settings, and in mainstream smoke, secondhand (sidestream) smoke (SHS), and thirdhand smoke exposures [1] [2] [3] [4] . The International Agency for Research on Cancer (IARC) listed SHS and air pollution as group 1 carcinogens in 2012 and 2013, respectively, and the World Health Organization (WHO) recently declared that "air pollution is the new tobacco" with~92% of the world's population living in regions that exceed WHO air quality limits [5] [6] [7] . In addition, the fact that climate changes are predicted to lead to increased air pollutants (e.g., particulate matter (PM)) from events such as promotion [44, 45] , and other inflammatory mediators important in early preneoplastic stages, such as TNF [46] , using RTPCR analysis in the epithelial cells. We also used a mouse alveolar macrophage cell line (MHS) to determine the effects of these LMW PAHs on another critical inflammatory cell type during promotion [47] [48] [49] and measured cytotoxicity and inflammatory mediator production via RTPCR. Lastly, based on the production of TNF by both cell types (epithelial and macrophage), we determined if recombinant TNF would influence GJIC and CX43 expression in the presence or absence of LMW PAHs. Collectively, these studies provide a novel link between GJIC and inflammation in the lung cells that are exposed to an environmental toxicant that is likely involved in tumor promotion and provide new data for future risk assessment.
Results

Cytotoxicity of the LMW PAHs in Lung Epithelial Cells and Macrophages
A dose response for the binary PAH mixture was done for all three cell lines ranging from 0-100 µM (Figure 1) , based on previous studies [36, 37] . In the C10 cells, the PAH mixture was not cytotoxic up to 60 µM, thus all subsequent studies were done at non-cytotoxic doses below 60 µM (Figure 1a ). Cytotoxicity was not observed in the E10 cells at 24 h, however, at 48 h, 40-80 µM was slightly yet significantly toxic and >80 µM was substantially toxic (Figure 1b ). In the MHS cells, cytotoxicity was observed at 40 µM, thus doses ≤20 µM were used for the remainder of the studies in the macrophage cell line (Figure 1c ). For all remaining epithelial cell studies, doses used were based on gap junction inhibition IC 50 (C10 cells, 40 µM prior to 24 h and 15 µM at 24 h), previously determined [37] , which are noncytotoxic doses.
Cancers 2019, 11, x 3 of 20 ligand 1 (KC), a key chemokine involved in the recruitment of neutrophils, an important cell type during lung tumor promotion [44, 45] , and other inflammatory mediators important in early preneoplastic stages, such as TNF [46] , using RTPCR analysis in the epithelial cells. We also used a mouse alveolar macrophage cell line (MHS) to determine the effects of these LMW PAHs on another critical inflammatory cell type during promotion [47] [48] [49] and measured cytotoxicity and inflammatory mediator production via RTPCR. Lastly, based on the production of TNF by both cell types (epithelial and macrophage), we determined if recombinant TNF would influence GJIC and CX43 expression in the presence or absence of LMW PAHs. Collectively, these studies provide a novel link between GJIC and inflammation in the lung cells that are exposed to an environmental toxicant that is likely involved in tumor promotion and provide new data for future risk assessment.
Results
Cytotoxicity of the LMW PAHs in Lung Epithelial Cells and Macrophages
A dose response for the binary PAH mixture was done for all three cell lines ranging from 0-100 μM (Figure 1) , based on previous studies [36, 37] . In the C10 cells, the PAH mixture was not cytotoxic up to 60 μM, thus all subsequent studies were done at non-cytotoxic doses below 60 μM (Figure 1a) . Cytotoxicity was not observed in the E10 cells at 24 h, however, at 48 h, 40-80 μM was slightly yet significantly toxic and >80 μM was substantially toxic (Figure 1b ). In the MHS cells, cytotoxicity was observed at 40 μM, thus doses ≤20 μM were used for the remainder of the studies in the macrophage cell line (Figure 1c ). For all remaining epithelial cell studies, doses used were based on gap junction inhibition IC50 (C10 cells, 40 μM prior to 24 h and 15 μM at 24 h), previously determined [37] , which are noncytotoxic doses. 
PAH-Induced Cytokine and Chemokine mRNA Expression in C10 Cells
We previously showed in our laboratory that the binary LMW PAH mixture used in these studies induces Kc, Il6, Mcp1, and Cox2 (Ptgs2) mRNA expression in C10 cells following 4 h of treatment [37] . In Figure 2 , we further demonstrate that Tnf, Il1β, Nalp3 (NLRP3), and Tlr4 transcripts are also significantly upregulated in response the same PAH mixture in the C10 cells. Because of these findings and the clear role of gap junctions in the mechanisms driving this LMW PAH-induced toxicity observed previously [36, 37, 40, 50] , we evaluated the effects of these inflammation pathways on GJIC using specific pharmacological inhibitors of inflammation in C10 and E10 epithelial cells. Figure 1. Cytotoxicity for epithelial (C10, E10) and macrophage (MHS) cell lines in response to LMW PAH exposure. In (a) C10 cells, (b) E10 cells, and (c) MHS cells for a dose response with the binary LMW PAH mixture (1:1 ratio of 1-methylanthracene and fluoranthene). Cytotoxicity was performed using an MTS assay at 24 and 48 h of treatment in cells that are serum deprived prior to treatment. For C10 and E10 cells, * p < 0.05 for treatment compared to control (DMSO); ** p < 0.05 100 µM dose compared to 40-80 µM dose for C10 cells. MHS cells: *, p < 0.05 treatments compared to control. + p < 0.05 20 µM compared to 40 µM; ** p < 0.05 40 µM compared to all other doses.
We previously showed in our laboratory that the binary LMW PAH mixture used in these studies induces Kc, Il6, Mcp1, and Cox2 (Ptgs2) mRNA expression in C10 cells following 4 h of treatment [37] . In Figure 2 , we further demonstrate that Tnf, Il1β, Nalp3 (NLRP3), and Tlr4 transcripts are also significantly upregulated in response the same PAH mixture in the C10 cells. Because of these findings and the clear role of gap junctions in the mechanisms driving this LMW PAH-induced toxicity observed previously [36, 37, 40, 50] , we evaluated the effects of these inflammation pathways on GJIC using specific pharmacological inhibitors of inflammation in C10 and E10 epithelial cells. Figure 2 . Expression of inflammatory mediator transcripts is increased in response to LMW PAH treatment in C10 cells. C10 cells following 4 h exposure to the PAH mixture (40 μM; 1:1 ratio of 1-methylanthracene and fluoranthene) were then evaluated using qRT-PCR. * p < 0.05 PAH treatment compared to control (DMSO). Tnf, tumor necrosis factor; Il1β, interleukin 1β; Nalp3, NACHT, LRR and PYD domains-containing protein 3 (NLRP3); Tlr4, toll-like receptor 4. Experiments repeated 2 times; n = 3 per treatment per experiment.
PAH-Induced Inhibition of Gap Junction Activity Is Prevented in Epithelial Cells in Response to a PanInflammation Inhibitor
We previously established that this binary PAH mixture inhibited GJIC in C10 cells at both the 4 h (early) and 24 h (late) time points in C10 cells, and that these PAHs elicited upregulation of cytokines and chemokine mRNA expression. Thus, to investigate potential pathways involved in these mechanisms, we inhibited several inflammation pathways at both time points in cells treated with 40 or 15 μM binary PAH mixture, respectively. Using the MTS cytotoxicity assay, we not observe any toxicity at the inhibitor doses used in any of the cell lines (Bauer, A.K.; Romo, D. University of Colorado, Anschutz Medical Campus, Aurora, CO, USA, 2019). At 4 h, we did not observe any significant effects of the anti-inflammatory compounds on GJIC inhibition in C10 (Figure 3a ,b) or E10 cells ( Figure 3c,d) ; see Figure S1 . Although in the E10 cells, parthenolide in combination with PAHs was close to significant (p < 0.08) and the image in Figure 3d supports this finding compared to the PAH treatment without PTL. However, at the 24 h time point, parthenolide reversed PAH-induced inhibition in C10 and E10 cells while no other compounds had an effect (Figure 4a-d ; see Figure S2 ). In addition, the CX43 protein at 24 h was significantly decreased in the C10 cells in response to the binary PAH mixture (15 μM), however parthenolide also significantly reversed the effect of the PAHs on CX43 protein expression ( Figure 5 ). Expression of inflammatory mediator transcripts is increased in response to LMW PAH treatment in C10 cells. C10 cells following 4 h exposure to the PAH mixture (40 µM; 1:1 ratio of 1-methylanthracene and fluoranthene) were then evaluated using qRT-PCR. * p < 0.05 PAH treatment compared to control (DMSO). Tnf, tumor necrosis factor; Il1β, interleukin 1β; Nalp3, NACHT, LRR and PYD domains-containing protein 3 (NLRP3); Tlr4, toll-like receptor 4. Experiments repeated 2 times; n = 3 per treatment per experiment.
PAH-Induced Inhibition of Gap Junction Activity Is Prevented in Epithelial Cells in Response to a Pan-Inflammation Inhibitor
We previously established that this binary PAH mixture inhibited GJIC in C10 cells at both the 4 h (early) and 24 h (late) time points in C10 cells, and that these PAHs elicited upregulation of cytokines and chemokine mRNA expression. Thus, to investigate potential pathways involved in these mechanisms, we inhibited several inflammation pathways at both time points in cells treated with 40 or 15 µM binary PAH mixture, respectively. Using the MTS cytotoxicity assay, we not observe any toxicity at the inhibitor doses used in any of the cell lines (Bauer, A.K.; Romo, D. University of Colorado, Anschutz Medical Campus, Aurora, CO, USA, 2019). At 4 h, we did not observe any significant effects of the anti-inflammatory compounds on GJIC inhibition in C10 (Figure 3a ,b) or E10 cells ( Figure 3c,d) ; see Figure S1 . Although in the E10 cells, parthenolide in combination with PAHs was close to significant (p < 0.08) and the image in Figure 3d supports this finding compared to the PAH treatment without PTL. However, at the 24 h time point, parthenolide reversed PAH-induced inhibition in C10 and E10 cells while no other compounds had an effect (Figure 4a-d ; see Figure S2 ). In addition, the CX43 protein at 24 h was significantly decreased in the C10 cells in response to the binary PAH mixture (15 µM), however parthenolide also significantly reversed the effect of the PAHs on CX43 protein expression ( Figure 5 ).
Chemokine Upregulation in Response to LMW PAHs: Inhibition with Anti-Inflammatory Compounds
Kc transcript expression was determined after 4 h exposure to the PAHs at the same doses used for the GJIC experiment and revealed that only parthenolide inhibited PAH-induced Kc expression in C10 cells (Figure 6a ). However, in E10 cells (Figure 6b) , parthenolide, ACHP, and CLI-095 all inhibited PAH-induced Kc expression. As a result, we then measured secreted KC via ELISA in media from C10 cells exposed to parthenolide in the presence of the binary LMW PAH mixture. The PAHs significantly increased KC protein secretion, while parthenolide inhibited the PAH-induced increase in KC at 4 and 8 h time points ( Figure 6 ). Additionally, Tnf transcripts were measured in both cell lines ( Figure S3 ). Tnf was significantly induced in response to the LMW PAHs in both cell lines, although to a greater extent in the E10 cells, compared to controls. However, parthenolide significantly inhibited PAH-induced Tnf in both C10 and E10 cells.
Production of Cytokines and Chemokines in MHS Cells in Response to LMW PAHs: Effects of Anti-Inflammatory Compounds
MHS, an alveolar macrophage cell line, was used to examine the production of cytokines and chemokines in response to the binary PAH mixture in an inflammatory cell type frequently observed in response to pulmonary insults. We chose cytokines and chemokines that we previously observed in response to these PAHs in epithelial cells (C10 cells) and that are reflective of acute inflammatory responses [51, 52] . The MHS cells were treated for 4 h with several non-cytotoxic doses of the binary PAH mixture (0-20 µM) followed by quantitative RT-PCR (qRT-PCR) analysis; Figure 7a demonstrates the responses at the 20 µM dose and Table 1 the responses at all doses of the binary PAH mixture. Cox2 and Tnf mRNA expression significantly increased in response to the PAH mixture at both 15 and 20 µM doses, whereas Kc and Il6 increased at 20 µM only. However, Il1β significantly increased from 10-20 µM doses. Mcp1 was not significantly changed in response to any of the doses in MHS cells. We then determined if parthenolide could inhibit Tnf expression following PAH treatment (Figure 7b ). Parthenolide significantly inhibited Tnf expression following PAH treatment, further supporting Tnf use in recombinant cytokine studies. In addition, PAH-induced Kc mRNA expression was also significantly reduced in response to parthenolide in MHS cells. Figure S1 ). (c) E10 cells were treated the same as the C10 cells with these inhibitors (parthenolide, ACHP, CLI-095, glyburide, and indomethacin). * p < 0.05 inhibitors or inhibitors + PAH treatment compared to control (DMSO); +, p < 0.05 indomethacin + PAH treatment compared to PAH without inhibitors (white bar on right). (d) Representative images of E10 cells following the SL/DT assay in response to the PAHs and parthenolide (all other inhibitor combinations shown in Figure S1 ). Experiments were repeated 3 times; n = 3 per treatment per experiment. PTL, parthenolide. Magnification 100×. the PAHs and parthenolide (all other inhibitor combinations shown in Figure S1 ). (c) E10 cells were treated the same as the C10 cells with these inhibitors (parthenolide, ACHP, CLI-095, glyburide, and indomethacin). * p < 0.05 inhibitors or inhibitors + PAH treatment compared to control (DMSO); +, p < 0.05 indomethacin + PAH treatment compared to PAH without inhibitors (white bar on right). (d) Representative images of E10 cells following the SL/DT assay in response to the PAHs and parthenolide (all other inhibitor combinations shown in Figure S1 ). Experiments were repeated 3 times; n = 3 per treatment per experiment. PTL, parthenolide. Magnification 100×. 
Chemokine Upregulation in Response to LMW PAHs: Inhibition with Anti-Inflammatory Compounds
Kc transcript expression was determined after 4 h exposure to the PAHs at the same doses used for the GJIC experiment and revealed that only parthenolide inhibited PAH-induced Kc expression in C10 cells (Figure 6a ). However, in E10 cells (Figure 6b) , parthenolide, ACHP, and CLI-095 all inhibited PAH-induced Kc expression. As a result, we then measured secreted KC via ELISA in media C10 cells were pre-treated for 1 h with 10 µM parthenolide (PTL) prior to treatment with the LMW PAH mixture (15 µM; 1:1 ratio of 1-methylanthracene and fluoranthene) for 24 h. Experiment repeated 4 times; n = 3 per treatment per experiment. A representative CX43 immunoblot is depicted above the graph (* p < 0.05 for treatment compared to control), PAH treatment and PAH treatment in the presence PTL ( + p < 0.05 for PAH compared to PAH plus PTL), and PTL alone (** p < 0.05 PTL compared to control). CX43 protein expression (upper blot) is normalized to β actin (ACTB, lower blot). C, cntl, control (DMSO); P, PAH, LMW PAH mixture; I, PTL, parthenolide (inhibitor); I + P, parthenolide plus PAH treatment. 
Production of Cytokines and Chemokines in MHS Cells in Response to LMW PAHs: Effects of AntiInflammatory Compounds
MHS, an alveolar macrophage cell line, was used to examine the production of cytokines and chemokines in response to the binary PAH mixture in an inflammatory cell type frequently observed in response to pulmonary insults. We chose cytokines and chemokines that we previously observed in response to these PAHs in epithelial cells (C10 cells) and that are reflective of acute inflammatory responses [51, 52] . The MHS cells were treated for 4 h with several non-cytotoxic doses of the binary PAH mixture (0-20 μM) followed by quantitative RT-PCR (qRT-PCR) analysis; Figure 7a demonstrates the responses at the 20 μM dose and Table 1 We then investigated the possibility that a cytokine, TNF, could influence gap junction dysfunction based on our previous studies [36] . These results herein with inhibitors of inflammation provided further evidence that the effects of TNF were downstream of NFκB and additional pathways (see Figure 2 , Figure 7 and Figure S3 ) in this lung cell model for both the epithelial cells and macrophages. In addition, one study using WB rat liver epithelial cells demonstrated that TNF inhibited GJIC [53] . We first demonstrated that TNF in the presence or absence of 15 µM binary PAH mixture was not cytotoxic (Figure 8a ). We then evaluated the ability of TNF to inhibit GJIC in C10 epithelial cells. rTNF increasingly inhibited GJIC between the doses of 1 to 20 ng/mL at 24 h (Figure 8b) . At 4 h, rTNF significantly inhibited GJIC at all doses, albeit only a 15% reduction as compared to a 25% reduction in gap junction activity using the lowest dose (1 ng/mL rTNF) at 24 h. Thus, we chose to do all following experiments at 24 h. inhibited GJIC [53] . We first demonstrated that TNF in the presence or absence of 15 μM binary PAH mixture was not cytotoxic (Figure 8a ). We then evaluated the ability of TNF to inhibit GJIC in C10 epithelial cells. rTNF increasingly inhibited GJIC between the doses of 1 to 20 ng/mL at 24 h ( Figure  8b ). At 4 h, rTNF significantly inhibited GJIC at all doses, albeit only a 15% reduction as compared to a 25% reduction in gap junction activity using the lowest dose (1 ng/mL rTNF) at 24 h. Thus, we chose to do all following experiments at 24 h. Next, we determined if rTNF would increase the inhibitory effects of the PAH mixture on GJIC. We used a very low dose of rTNF (1 ng/mL) added to the binary PAH mixture (8 or 15 μM), which are doses that mimic the lung microenvironment following exposure to PAHs. As observed in Figure  9A , the rTNF added to the 40 μM PAH mixture did not significantly alter inhibition of GJIC at 4 h as compared to the 40 μM PAH mixture containing no rTNF. However, at 24 h the addition of rTNF to the PAH mixture significantly increased inhibition of GJIC, as compared to the PAH mixture without rTNF ( Figure 9B ). To obtain a more robust response of this rTNF effect, we used ~1/2 the dose of the PAH mixture (8 μM) and repeated the study at the 24 h time point (Figure 9B, right) . The addition of 1 ng/mL rTNF to 8 μM of the PAH mixture, significantly increased the inhibition of GJIC above that observed with the PAH mixture alone, supporting the concept of a toxicant/inflammatory mediator combination effect in the lung. Lastly, we determined if this rTNF effect not only affected gap junction Figure 8 . Recombinant TNF (rTNF) is not cytotoxic to C10 cells but does inhibit GJIC. (a) Cytotoxicity in C10 cells was assessed using the MTS assay at 24 h to determine any rTNF-induced toxicity or toxicity due to rTNF in the presence to 15 µM LMW PAH mixture (1:1 ratio of 1-methylanthracene and fluoranthene). No cytotoxicity was observed. (b) GJIC was measured using the SL/DT assay at both 4 and 24 h time points with rTNF alone. * p < 0.05 rTNF treatment compared to control; + p < 0.05 rTNF at 24 h compared to 4 h. rTNF, recombinant TNF; PAH, LMW PAH mixture described above. Experiments repeated 3 times with an n = 3 per treatment per experiment.
Next, we determined if rTNF would increase the inhibitory effects of the PAH mixture on GJIC. We used a very low dose of rTNF (1 ng/mL) added to the binary PAH mixture (8 or 15 µM), which are doses that mimic the lung microenvironment following exposure to PAHs. As observed in Figure 9A , the rTNF added to the 40 µM PAH mixture did not significantly alter inhibition of GJIC at 4 h as compared to the 40 µM PAH mixture containing no rTNF. However, at 24 h the addition of rTNF to the PAH mixture significantly increased inhibition of GJIC, as compared to the PAH mixture without rTNF ( Figure 9B ). To obtain a more robust response of this rTNF effect, we used~1/2 the dose of the PAH mixture (8 µM) and repeated the study at the 24 h time point (Figure 9B, right) . The addition of 1 ng/mL rTNF to 8 µM of the PAH mixture, significantly increased the inhibition of GJIC above that observed with the PAH mixture alone, supporting the concept of a toxicant/inflammatory mediator combination effect in the lung. Lastly, we determined if this rTNF effect not only affected gap junction function but also the level of the gap junction protein, CX43 ( Figure 10 ). As expected, at the higher PAH level, the CX43 protein was repressed, but not significantly different from the PAH alone (Figure 10  left) , whereas at the lower PAH dose, the level of CX43 repression significantly differed from the PAH and rTNF alone (Figure 10 right) . Thus, lower levels of PAH in combination with a cytokine led to significant effects on gap junctions, a biomarker for tumor promotion. 
Discussion
Our overall hypothesis for the studies herein was that inflammatory mediators resulting from treatment with these environmentally relevant LMW PAHs negatively influence GJIC in lung epithelial cells. We used both epithelial and macrophage cell lines to show that these PAH-induced cytokines and chemokines not only originate from the epithelial cells, but also the lung macrophages, at PAH doses that are non-cytotoxic. This finding is important given that the lung microenvironment is so complex, and inflammation is involved in the early stages of cancer development that is typically dependent on immune cells, particularly the macrophages [28] . Due to our recent study implicating eicosanoid pathway involvement [49] , we determined which key inflammation pathways were involved in PAH-mediated dysregulation of GJIC using several pathway specific pharmacological inhibitors. Namely, cells were preincubated with (1) parthenolide, a pan-inflammation blocker that inhibits NFκB, AP1, and NALP3 inflammasome pathways [54, 55] . (2) ACHP that inhibits IκB preventing the activation of NFκB, which is a transcription factor involved in many inflammation pathways including signaling downstream of TNF [52] . (3) CLI-095 that blocks TLR4 [56] , which is a receptor and signaling pathway that is upstream of many pro-inflammatory cytokines/chemokines such as TNF and KC [57] . (4) Glyburide that inhibits NALP3, which is a component of the inflammasome and coded by the NLRP3 gene [58] . (5) Indomethacin that blocks COX1/2, which is a critical pathway leading to prostaglandin production [40] . Parthenolide was the only inhibitor that reversed PAH-induced dysfunction of GJIC in the C10 cells at 24 h, but not 4 h. In E10 cells, the GJIC response with parthenolide was similar to the C10 cells at 24 h, however at 4 h, parthenolide exposure in combination with the PAHs was close but not significantly different than PAH treatment (Figure 3c,d) . PAH metabolism could be involved after 8 h, but not prior to 8 h as these LMW PAHs are not metabolized in C10 cells indicating that the cellular events before 8 h are functions of the non-metabolized parent compounds [40] . However, PAH byproducts might be involved at later times in which~50-60% of the PAHs are metabolized at 24 h [40] . Thus, this suggests that the PAH metabolites or the metabolites in conjunction with the remaining parent compounds are eliciting these effects on GJIC at 24 h, further supported by the parthenolide-induced reversal of PAH-induced CX43 protein repression ( Figure 5 ). Collectively, it appears that a more pan-inflammation inhibition of primary known pathways that lead to pro-inflammatory cytokine and chemokine production are necessary to elicit effects on gap junctions following PAH exposures because none of the specific inhibitors had any effect on gap junctions in C10 or E10 cells (see Figure 11 ). . rTNF-induced repression of CX43 protein expression at 24 h is enhanced following coexposure to rTNF and the lower LMW PAH dose (8 μM). Both the high (15 μM) and low (8 μM) doses of the LMW PAH mixture (1:1 ratio of 1-methylanthracene and fluoranthene) were used to evaluate the effect of rTNF on CX43 protein expression using immunoblots. CX43 protein expression (upper Figure 10 . rTNF-induced repression of CX43 protein expression at 24 h is enhanced following co-exposure to rTNF and the lower LMW PAH dose (8 µM). Both the high (15 µM) and low (8 µM) doses of the LMW PAH mixture (1:1 ratio of 1-methylanthracene and fluoranthene) were used to evaluate the effect of rTNF on CX43 protein expression using immunoblots. CX43 protein expression (upper blot) is normalized to bactin (lower blot). rTNF (1 ng/mL), LMW PAHs at both doses, and the combinations of both doses with rTNF are shown. The immunoblot depicted at the top is representative of 3 experiments with an n = 3 per treatment group per experiment. * p < 0.05 all treatments compared to the control (DMSO); + p < 0.05 rTNF compared to 15 µM PAH or rTNF plus 15 µM PAH; ** p < 0.05 8 µM PAH plus rTNF compared to either rTNF or 8 µM PAH alone. C, Cntl, control (DMSO); rTNF, rT, recombinant TNF (1 ng/mL); PAH, P, LMW PAH mixture; rT + P, rTNF plus PAH treatment. To provide evidence that cytokines can act more directly in dysregulating gap junctions in our model, we chose a PAH-induced cytokine, TNF, observed in the epithelial and macrophage cells (Figures 2,7 and Figure S3 ). TNF is a pro-inflammatory cytokine with known tumor promoting and tumor repressing properties studied in many types of cancers, including lung, and is involved in both acute and chronic inflammation [51] . This cytokine is downstream of both NFκB and AP-1 transcription factor pathways, and thus is also downstream of TLR4 signaling [51] . Once TNF binds to its receptors (TNFR1 and TNFR2), the NFκB pathway is triggered, which in turn activates the NALP3 inflammasome [59] . Thus, this cytokine is connected to the pathways inhibited via parthenolide in our model system. Additionally, TNF heterozygote (−/+) mice were found to develop less lung tumors than wildtype control mice in urethane-induced lung cancer [60] and TNF is in a critical chromosomal loci for both cancer and many lung inflammatory diseases [25] , further supporting a role of TNF in the development of lung disease and cancer. Our novel data using rTNF provides the needed evidence that cytokines can act alone to trigger the dysfunction of GJIC in lung epithelial cells at relevant doses in addition to providing evidence that these PAHs that persist in the cells can act together with cytokines to elicit adverse effects on lung cells (see Figures 9,10) . Figure 11 depicts the findings from these studies in lung cells.
Other groups have determined the effects of rTNF in liver and lung alveolar type II cell lines [53, 61, 62] . In WB liver cells, an oval cell or stem-like cell line, rTNF alone elicited dysregulation of GJIC only after 24 h at similar doses to those used in our studies (1-20 ng/mL). These authors did not observe any alterations in GJIC prior to 24 h with rTNF, but only assessed a 1 h time point, whereas we examined a 4 h time point in the C10 cells and did see significant dysregulation (~20%) at all doses tested. LMW PAHs were also individually used (fluoranthene, phenanthrene, and pyrene) in the WB cells, however, these LMW PAHs were not found to further exacerbate the rTNF-induced dysregulation of GJIC at 24, unlike our findings in lung at lower PAH doses [53] . We also used the lowest rTNF dose (1 ng/mL) to represent a more physiological dose in our model and probe for potential interactions with PAH-induced responses on GJIC and Cx43 protein expression, which is also why we used a lower dose (8 μM) of the LMW PAH mixture (Figures 9,10 ). These doses were also lower than the doses used in the liver cell model suggesting the potential that the lung cells are not as metabolically active at 24 h (noted above and in [40] ), and that our parent compounds are still influencing the observed responses at 24 h. In addition to affecting gap junctions, rTNF was shown to work alone or in coordination with B[a]P (a HMW PAH) to upregulate CYP1B1 in a rat alveolar Figure 11 . A schematic demonstrating the effects of inflammation on GJIC. PAHs activate MAP kinase pathways, such as p38 MAP kinase and inflammatory mediator pathways, such as cytokines (TNF, KC, and others). Some of these pathways then lead to the inhibition of GJIC. Blue indicates inhibition with PTL. Red indicates inhibition of gap junctions. MΦ, macrophage; PTL, parthenolide; p38, p38 MAP kinase.
To provide evidence that cytokines can act more directly in dysregulating gap junctions in our model, we chose a PAH-induced cytokine, TNF, observed in the epithelial and macrophage cells (Figure 2 , Figure 7 and Figure S3 ). TNF is a pro-inflammatory cytokine with known tumor promoting and tumor repressing properties studied in many types of cancers, including lung, and is involved in both acute and chronic inflammation [51] . This cytokine is downstream of both NFκB and AP-1 transcription factor pathways, and thus is also downstream of TLR4 signaling [51] . Once TNF binds to its receptors (TNFR1 and TNFR2), the NFκB pathway is triggered, which in turn activates the NALP3 inflammasome [59] . Thus, this cytokine is connected to the pathways inhibited via parthenolide in our model system. Additionally, TNF heterozygote (−/+) mice were found to develop less lung tumors than wildtype control mice in urethane-induced lung cancer [60] and TNF is in a critical chromosomal loci for both cancer and many lung inflammatory diseases [25] , further supporting a role of TNF in the development of lung disease and cancer. Our novel data using rTNF provides the needed evidence that cytokines can act alone to trigger the dysfunction of GJIC in lung epithelial cells at relevant doses in addition to providing evidence that these PAHs that persist in the cells can act together with cytokines to elicit adverse effects on lung cells (see Figures 9 and 10) . Figure 11 depicts the findings from these studies in lung cells.
Other groups have determined the effects of rTNF in liver and lung alveolar type II cell lines [53, 61, 62] . In WB liver cells, an oval cell or stem-like cell line, rTNF alone elicited dysregulation of GJIC only after 24 h at similar doses to those used in our studies (1-20 ng/mL). These authors did not observe any alterations in GJIC prior to 24 h with rTNF, but only assessed a 1 h time point, whereas we examined a 4 h time point in the C10 cells and did see significant dysregulation (~20%) at all doses tested. LMW PAHs were also individually used (fluoranthene, phenanthrene, and pyrene) in the WB cells, however, these LMW PAHs were not found to further exacerbate the rTNF-induced dysregulation of GJIC at 24, unlike our findings in lung at lower PAH doses [53] . We also used the lowest rTNF dose (1 ng/mL) to represent a more physiological dose in our model and probe for potential interactions with PAH-induced responses on GJIC and Cx43 protein expression, which is also why we used a lower dose (8 µM) of the LMW PAH mixture (Figures 9 and 10 ). These doses were also lower than the doses used in the liver cell model suggesting the potential that the lung cells are not as metabolically active at 24 h (noted above and in [40] ), and that our parent compounds are still influencing the observed responses at 24 h. In addition to affecting gap junctions, rTNF was shown to work alone or in coordination with B[a]P (a HMW PAH) to upregulate CYP1B1 in a rat alveolar type II cell line (RLE-6TN), potentially increasing the metabolism of procarcinogens and therefore playing a role in early tumor development [61] . Lastly, rTNF combined with B[a]P in these RLE-6TN cells also increased reactivity with DNA as indicated by B[a]P-induced DNA adduct formation potentially leading to genotoxic events. Additionally, TNF increased mRNA production of inflammatory mediators, namely iNos, Cox2, Il6, and Il1β [62] , some of which were cytokines detected in our studies. However, the dose of rTNF used for these RLE-6TN cell line studies was 20 ng/mL [61, 62] and therefore the physiological relevance of this dose comes into question.
We previously published data that provided evidence that the LMW PAH mixture elicited a co-carcinogenic effect when combined with B[a]P in the C10 cells [35] . In these studies, we observed significant increases in DNA adduct formation resulting from the primary B[a]P metabolite (BPDE) combined with the same two LMW PAHs in our mixture used for the present studies. In addition, we observed significant increases in GJIC dysregulation with the B[a]P and LMW PAH combination, as well as an increase in COX-2 mRNA expression, all supporting early stage tumor promotion associated phenotypes. However, in these studies we did not directly assess promotion per se because we applied the toxicants at the same time and thus concluded that at the least, these LMW PAHs should be considered co-carcinogens. However, currently, they are considered non-toxic, non-genotoxic, and non-carcinogenic in many cellular models [50, 63, 64] . DNA adduct formation is a hallmark of cancer described by Hanahan and Weinberg (2011) that contributes to genome instability and mutations [28] , and is a key step during the initiation stage of multistage cancer processes. However, other important events that occur during tumor promotion involve both gap junction dysfunction and inflammation.
Gap junction dysregulation and dysfunction is part of the evasion of growth suppression and the current hypothesis is that gap junctions can act as tumor suppressors, at least in early cancer development [29] . Connexins and gap junctions in lung epithelial cells are involved in homeostatic functions such as the regulation of surfactant secretion in type II cells, calcium signaling between type I and II cells, ciliary beating, and other cell signaling events [42] . A disruption in these functions could lead to adverse effects and more injury in these cells, such as alterations in growth and the potential link to acute lung injury or acute respiratory distress syndrome (ARDS) that requires cell-cell communication [42, 65] . In addition, idiopathic pulmonary fibrosis patients had decreased CX43 expression [38] and a mouse model with both Cx40 −/− and Cx43 −/− (endothelial) KO mice had fibrosis like symptoms 8 wks after birth [66] . However, it is currently unclear how to account for the other research supporting a pro-inflammatory role for gap junctions in the lung [67] . Interestingly, the liver may be a potential clue where in a chronic liver model, increases in CX43 expression are associated with inflammation; when CX43 is blocked in this liver model, the liver damage is far worse suggesting the CX43 expression is involved in an adaptive protective response [68] .
Tumor promoting inflammation is also a hallmark of cancer [28] and our laboratory and many others have established a role for inflammatory pathways, such as TLR4, TNF, NFκB, among many others, in lung cancer development [25, 60, 69, 70] . TLR4 is a complicated pathway; in acute lung inflammation/injury models, TLR4 is typically pro-inflammatory [71, 72] , whereas in lung cancer, appears to be protective [73] . In astrocytes, CX43 was degraded in response to acute LPS treatment [74] , while in C10 cells, bronchoalveolar lavage from Tlr4 −/− mice inhibited gap junctions and CX43 expression compared to wildtype mice [75] . Thus, it depends on acute versus chronic as to the involvement of the TLR4 pathway and the link to gap junctions.
Lastly, there are several future directions for our research. These studies did not investigate other lung expressed connexins, such as CX26 and CX32, the possibility of hemichannel involvement, nor tight junction protein involvement, all of which have potential roles in our LMW-PAH induced lung model [42] . Cross talk between tight junctions and connexins is commonly observed in lung [42] , with specific proteins like ZO-1 and CX43 directly interacting. Collectively, these novel studies addressing the association between inflammation and gap junctions in an environmentally relevant model provide additional empirical evidence for future risk assessments on these LMW PAHs to prevent adverse health effects as well as identifying potential new therapeutic targets, such as connexins, for early stage lung cancer.
Materials and Methods
Materials and Reagents
Parthenolide (pan-inflammation inhibitor: NFκB, AP-1, and NALP3 inflammasome pathway inhibitor) and ACHP (NFκB specific inhibitor) were purchased from TOCRIS (0610, 4547, Bristol, UK). Indomethacin (COX1/2 inhibitor) was purchased from Sigma-Aldrich (I7378, St. Louis, MO, USA). CLI-095 (TLR4 inhibitor) was purchased from InvivoGen (tlrl-cli95, San Diego, CA, USA). Fluoranthene was obtained from AccuStandard (H-118N, purity 97.2%, New Haven, CT, USA) and 1-methylanthracene from Crescent Chemical (DRE-C20834900, purity 99.5%, Islandia, NY, USA). Glyburide (Glybenclamide; NLRP3 inhibitor) was purchased from Novus (NBP2-30141, Centennial, CO, USA). All inhibitors and PAH were dissolved in DMSO (Thermo Fischer Scientific, Waltham, MA, USA), as done previously [36, 37, 40] . Recombinant mouse TNF-alpha (rTNF) was purchased from R&D systems (410-MT, Minneapolis, MN, USA).
Cell Line Maintenance and Experimental Design
Both the C10 and E10 cell lines, immortalized non-transformed alveolar type II cell lines, were obtained as a kind gift from Dr. Lori Nield (University of Colorado, Denver Anschutz Medical Center, CO, USA). These cell lines were originally derived from BALB mice [76, 77] and are ideal for our studies because they are from a progenitor cell type known to initiate non-small cell lung carcinomas [78, 79] . Cells were maintained in CMRL 1066 media (Thermo Fisher Scientific) containing 10% fetal bovine serum, 1% L-glutamine, and 1% Penicillin Streptomycin. Both C10 and E10 cells were grown to confluency and serum deprived for 24 h prior to treatment. C10 and E10 cells were pre-treated with inhibitors 1 h before treatment with 40 µM or 15 µM binary PAH mixture for 4 h and 24 h, respectively. Our LMW binary PAH mixture consisted of a 1:1 ratio of two prevalent LMW PAHs found environmentally and in secondhand smoke, 1-methylanthracene and fluoranthene. These doses and ratio for PAH exposure were used previously in the C10 cells in our lab and are the IC 50 for dysregulation of GJIC at 4 h (40 µM) or 24 h (15 µM) [36, 37, 40] . For the E10 cells, following cytotoxicity evaluation, we performed dose response studies for gap junction activity to determine doses, as was done previously with the C10 cells and determined similar IC50s to the C10 cells at both times, thus we used the same doses for the E10 cells.
MHS cells are an alveolar macrophage cell line originally derived from BALB/c mice [80] . MHS cells were maintained in RPMI media with 2 mM L-glutamine, 1% Penicillin Streptomycin, 10% FBS, 2.38 g HEPES (10 mM), 10 µL sodium pyruvate (1 mM), 2.25 g glucose, 0.75 g sodium bicarbonate, and 1.75 µL 2-mercaptoethanol. Cells were grown to confluency and serum deprived for 24 h prior to treatment. Cells were treated with ≤20 µM of the binary PAH mixture, a dose determined to be non-cytotoxic.
Cytotoxicity
Cytotoxicity was assessed in all cell lines using the CellTiter 96 Aqueous One Solution Cell Viability assay (MTS assay, Promega, Madison, WI, USA) following manufacturer's instructions. Cells were grown in 96 well cell culture plates and serum deprived for 24 h prior to treatment with PAH, pharmaceutic inhibitors, rTNF, or their combinations.
Scalpel Loaded/Dye-Transfer Assays to Measure Gap Junctional Intercellular Communication (GJIC)
GJIC activity was determined using the method described by Upham et al. (2011) [81] . C10 cells were grown to confluency and treated as noted above. Immediately following the treatment, cells were washed three times with PBS and in the presence of a Lucifer Yellow dye (1 mg/mL in PBS), three cuts were made with a steel scalpel blade. The dye was allowed to transfer between gap junctions for 3 min. The cells were then washed again with PBS three times and fixed with 4% formalin in PBS. The cut lines were imaged with an Eclipse TI-S microscope at 100× and captured using a DS-QiMc camera (Nikon Instruments, Melville, NY, USA). The area of dye spread, considered GJIC, was quantified using ImageJ software (http://imagej.nih.gov/ij/). Treatment groups were compared to DMSO, the vehicle control, for final fraction of control (FOC) percentages. Three images were taken of each individual line, three cuts were made per dish, and there were three dishes per treatment, for a total of n = 9.
KC Measurement via ELISA
KC protein levels were evaluated using the mouse CXCL1/KC DuoSet ELISA (DY453, R&D) following manufacturer's instructions. Cells were washed with saline before a 1 h treatment with inhibitor and a 4 h PAH treatments. At sample addition, the conditioned media retrieved was diluted 1:1 with reagent diluent (5% BSA in PBS) and incubated overnight in 96 well ELISA plate. The plate was read at 450 nm using the Tecan Infinite M200 Pro plate reader (Morrisville, NC, USA).
CX43 Protein Expression Using Immunoblots
Protein from C10 cells was extracted using 20% SDS containing Halt Protease & Phosphatase Single-Use Inhibitor Cocktail (Pierce, Waltham, MA, USA), similar to Osgood et al. (2013 and , [36, 37] ). Twenty µg of protein per sample were separated on a 12.5% SDS page gels and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Burlington, MA, USA). Anti-rabbit Cx43 antibody (cat# 3512s, Cell Signaling, Danvers, MA, USA) and anti-rabbit B-actin were diluted 1:1000 in Odyssey Blocking Buffer (cat# 927-50000, in 1× TBS) and incubated overnight at 4 degrees Celsius. Secondary antibodies used were IRDye800 CW goat anti-rabbit (1:10,000) for Cx43 and IRDye680 LT goat anti-mouse (1:20,000) for β-actin. Proteins were visualized using the Odyssey Imaging system (Licor, Lincoln, NE, USA) and quantified by densitometry using the Image Studio software (Licor).
Quantitative Reverse Transcriptase PCR (qRT-PCR)
One microgram of total RNA was reverse transcribed to cDNA [37] and amplified with gene-specific primers labeled with Power SYBR Green master mix (Applied Biosystems, Foster City, CA, USA) using an QuantStudio 3 Real time PCR (Applied Biosystems). Samples were normalized to the expression of 18S rRNA using the comparative CT method [82] . Sequences for the primers (Il1b, Tlr4, Nalp3) can be found in Table S1 or in previously published works (Kc, Mcp1, Cox2, Il6, 18S) [36, 37, 40] .
Conclusions
Our studies herein provide novel evidence that GJIC inhibition can be reversed in response to an anti-inflammatory inhibitor in lung epithelial cells. In addition, we show for the first time that a pro-inflammatory cytokine, such as TNF, can influence or potentially interact with an environmental toxicant, such as the PAHs, in lung epithelial cells to inhibit gap junction function as well as CX protein expression. Since we provide evidence that TNF originates from both epithelial cells or macrophages, this supports that both autocrine and paracrine mechanisms are involved. In the future, we will further investigate the mechanisms driving these observed responses, evaluate additional pathways for identification of biomarkers of exposure, and potential new therapeutic targets. 
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